FT Lex : Renault/Nissan: Ghosn concern

Renault/Nissan: Ghosn concern
Much of the tie-up’s success is down to the Renault chief — but he won’t be around forever

Some relationships endure hard times only to break up decades later. The successful tie-up between Renault and Nissan dates back to 1999 but could yet collapse. Its architect, Renault boss Carlos Ghosn, is intent on making such an outcome impossible. His efforts to deepen the alliance have a good chance of success. But he should take his foot off the pedal when it comes to pursuing merger talks.

The current set-up is idiosyncratic. Renault has effective control of its Japanese partner through a 43 per cent shareholding. Nissan has a 15 per cent stake in Renault and no voting rights, even though it has better earnings and prospects. Its profits accounted for 54 per cent of Renault’s total in 2017. Shares trade on a multiple of 8 times next year’s earnings, compared with 5 times for Renault.

Despite the odd capital structure, the tie-up has worked. The alliance — which Mitsubishi joined when Nissan took a 34 per cent stake in 2016 — shares research, purchasing and manufacturing functions. Ambitious plans are in place to find cost cuts and less tangible benefits worth a combined €10bn a year by 2022.

Investors might think “if it ain’t broke, why fix it?” But much of the success is down to the skills of Mr Ghosn, the ultimate multiculturalist. He will not be around forever, though he is likely to stay in charge of the alliance after stepping down as Renault’s chief executive, now expected to be before 2022. Another snag with the status quo is that the unusual capital structure deters investors. Merger rumours sent Renault’s share price soaring in March.

The roadblocks are significant. Nissan has said it does not want to sacrifice independence. The French government, which has a 15 per cent stake, would resist the job losses likely to result from a merger. The biggest obstacles are cultural, as demonstrated by the disastrous DaimlerChrysler pact in 1998. A repeat should be avoided. No deal would be better than a bad deal.

>>> Lowe's shareholder Pershing Square files with FTC, clearing way for potentia

Lowe's shareholder Pershing Square files with FTC, clearing way for potential activism
14 JUN 2018
Pershing Square, the investment firm run by Bill Ackman, has received early termination approval from the US Federal Trade Commission for an unspecified transaction in Lowe's Companies [NYSE:LOW], the North Carolina-based home improvement retailer.
The FTC notice, which was made public late Wednesday (13 June), named PS Holdings Independent Trust, a Pershing Square-related entity.
Several newswires reported on 23 May that Pershing Square had bought a stake in Lowe's worth about USD 1bn. The Wall Street Journal reported at the time that the investment was expected to be an amicable one and that Ackman supported Marvin Ellison, appointed on 22 May as Lowe's new chief executive officer effective 2 July.
Since those reports in May, Ackman does not appear to have taken any actions typically associated with activist investors.
A passive investor that acquires more than USD 84.4m worth of stock and, using the passive investor exemption, does not make an HSR filing, may subsequently decide to play a more active role. But the investor cannot buy any more shares without first making an HSR filing.
PS Holdings Independent Trust, the entity listed on Wednesday's FTC notice, also appeared on an FTC notice dated 30 March 2018 in regards to United Technologies [NYSE:UTX]. Pershing Square's stake in UTX had previously been reported in February, when The Wall Street Journal said Ackman viewed UTX as a good company and had not decided if he would be an activist in it. In May, less than two months after receiving FTC clearance, Ackman reportedly called for a breakup of the company.
David Batchelder, co-founder of Relational Investors, became a Lowe's board member in March under an agreement with D.E. Shaw.

>>> US Gapping down


Gapping down
In reaction to disappointing earnings/guidance
:

  • TLRD -18%, MIK -15.6%, FRED -2.9%

Other news:

  • KTWO -7.3% (announces private offering of $65.0 million aggregate principal amount of convertible senior notes)
  • CISN -3.1% (announces 12.0 mln share offering by selling shareholders)
  • MYL -3% (received FDA update concerning pending approval for generic Advair Diskus; FDA identified minor deficiencies to be relayed in Complete Response Letter on June 27, 2018)
  • CGC -2.4% (to offer C$400 mln aggregate principal amount of convertible senior notes due 2023 )
  • EXK -2.2% (entered into at-the-market offering of up to $35.7 mln )
  • ASUR -2.1% (to offer common stock in an underwritten public offering by Asure and iSystems Holdings selling stockholder)
  • TAL -1.9% (following Muddy Waters report)

Analyst comments:

  • TEX -4.2% (downgraded to Sell from Neutral at Goldman)
  • ORCL -2.3% (downgraded to Neutral from Overweight at JP Morgan)
  • KSS -1.7% (downgraded to Neutral from Buy at Citigroup)
  • XPO -1.7% (downgraded to Neutral from Buy at BofA/Merrill)
  • SPOT -0.5% (initiated with a Hold at Deutsche Bank; tgt $155)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:

  • N/A.

Other news:

  • TLGT +19.3% (received FDA approval of the Company's abbreviated new drug application of Diflorasone Diacetate Ointment 0.05%; planning to launch this product in the third quarter of 2018)
  • APTO +10.5% (enters into a license agreement with CrystalGenomics for China rights to CG-806 to develop and commercialize CG-806)
  • NVAX +4.3% (New England Journal of Medicine publishes Novavax' NanoFlu clinical trial data)
  • PVTL +3.8% (continued strength following earnings)
  • ARGX +2.6% (announces results from its Phase 1 clinical trial evaluating a subcutaneous formulation of efgartigimod)
  • GSK +2.1% (GSK received FDA update concerning pending approval for generic Advair Diskus; FDA identified minor deficiencies to be relayed in Complete Response Letter on June 27, 2018)
  • NUAN +2% (following CNBCFastMoney mention)
  • SAGE +1.3% (SAGE Therapeutics and Shionogi & Co enter strategic collaboration to develop and commercialize SAGE-217)

Analyst comments:

  • NUS +1% (initiated with a Buy at Jefferies)

>>> US Early premarket gappers

Early premarket gappers

Gapping up:

  • NVAX +10.6%, TLGT +10.1%, PVTL +4.5%, FRED +2.9%, NUAN +1.8%, GSK +1.5%, FOXA +0.5%

Gapping down:

  • TLRD -17.2%, KTWO -7.3%, MYL -4.6%, EXK -4.3%, CISN -3.1%, ASUR -2.1%, CGC -2%, CMCSA -0.6%, SHAK -0.6%